

Vienna, Austria

Annual Congress of the
European Association of Nuclear Medicine
October 21 –25, 2017
Vienna, Austria

Pre-Congress Symposium 3 (Dosimetry/Radiation Protection) **Saturday, October 21, 2017, 09:00 – 12:00**

Session Title

Clinical Introduction of New Radiotherapeutics: Challenges and Opportunities

Chairs

Glenn Flux (London)

Mark Konijnenberg (Rotterdam)

Programme

09:00 – 09:15 Glenn Flux (London) & Mark Konijnenberg (Rotterdam): Introduction

09:15 – 09:30 Ashish Soman (Sydney): Phosphorous-32 Microparticles

09:30 – 09:45 Frank Nijssen (Deventer): Holmium-166 Microspheres

09:45 – 10:00 Thibault Mauxion (Nantes): Y-90 Glass Microspheres

10:00 – 10:15 Jürgen Gay (Berlin): Alpha Therapy with Radium-223 and Thorium-227

10:15 – 10:45 Coffee Break

10:45 – 11:00 Jostein Dahle (Oslo): Treatment of NHL with Lutetium-177 Labelled Anti-CD37 Antibodies

11:00 – 11:15 Maurizio Mariani (Saint-Genis-Pouilly): Lutetium-177 Peptides and Antibodies

11:15 – 11:30 Matt Harris (Sydney): Copper Isotopes for Imaging and Therapy

11:30 – 12:00 Panel Discussion: Opportunities for Collaborations

Educational Objectives

1. To learn of new radiotherapeutics currently emerging.
2. To gain an understanding of the issues involved in bringing a new radiotherapeutic into clinical practice and maintain its registration.
3. To understand the development of new patient-specific radiotherapeutic drugs.
4. To realize the various methods for optimising radiotherapeutic treatment schedules.

Summary

An ever increasing number of commercial radiotherapeutics are entering the clinic, signalling a dramatic change from the small number of well established products, some of which have been used for over 60 years. There are estimated to be 10-20 new products in development or in early phase clinical trials, and the market is predicted to grow significantly in the foreseeable future. This explosion of activity brings unprecedented opportunities for nuclear medicine, but also a host of challenge relating to regulations, variations in procedures and practice throughout Europe. Large investments are involved with data acquisition for licensing product approval and clinical optimisation of a new agent, often in an already competitive market.

With a view to pursuing the common aim of promoting the use of radiotherapeutics for the treatment of cancer this symposium will share the experiences of established and new radiopharmaceutical companies and will consider how the nuclear medicine commercial, clinical and research communities can best cooperate for the benefit of the patient.